This retrospective cohort study showed no significant difference in the occurrence of hemorrhage or unfavorable 90-day clinical outcomes when a GP IIb/IIIa inhibitor (eptifibatide) was used during EVT in CeAD-related strokes. This evidence concerns the gene ITGA2B and hemorrhage.